JAHA:高敏感性C反应蛋白预测心血管疾病的风险!

2017-10-25 xing.T MedSci原创

hs-CRP的累积暴露与随后增加的CVD和心肌梗死风险呈剂量依赖关系。

高敏C反应蛋白(hs-CRP)这一指标与心血管疾病(CVD)风险增加有关。近日,心血管疾病领域权威杂志JAHA上发表了一篇研究文章,这项研究的目的是描述累积暴露于升高的hs-CRP与心血管事件发生之间的相关性。

在2006年,2008年和2010年,研究人员共3次测量了53065名参与者的hs-CRP水平。hs-CRP的累积暴露通过每个时间间隔的平均hs-CRP水平加权和(水平×时间)来计算得到。参与者分为非暴露组(3次检查中hs-CRP<3.0mg/L),1次暴露组(3次检查中有1次hs-CRP≥3.0mg/L),2次暴露组(3次检查中的2次hs-CRP≥3.0mg/L),3次暴露组(3次检查中均有hs-CRP≥3.0mg/L)。研究人员采用Cox比例风险模型评估累积hs-CRP与CVD事件之间的关联。

研究显示随着hs-CRP暴露的年数增加,患有CVD和心肌梗死风险与其呈剂量反应关系。3次暴露组的参与者CVD风险明显增加,风险比(95%可信区间)为1.38(1.11-1.72),而2次暴露组参与者为2.13(1.07-1.52),而1次暴露组参与者为1.13(0.97-1.31)(P<0.05);同时,对于心肌梗死也观察到相似和显著的相关性,其风险比(95%可信区间)分别为2.13(1.42-3.18),1.60(1.12-2.27)和1.57(1.17-2.10)。脑卒中和累积hs-CRP之间的关联无统计学意义(P=0.360)。

由此可见,hs-CRP的累积暴露与随后增加的CVD和心肌梗死风险呈剂量依赖关系。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1267570, encodeId=d2a8126e570af, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Oct 27 02:07:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297822, encodeId=2172129e82276, content=<a href='/topic/show?id=4eca5598c7' target=_blank style='color:#2F92EE;'>#C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5598, encryptionId=4eca5598c7, topicName=C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20b5274, createdName=JR19860219, createdTime=Fri Oct 27 02:07:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388380, encodeId=4a0213883809d, content=<a href='/topic/show?id=7ef25e5346b' target=_blank style='color:#2F92EE;'>#敏感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57534, encryptionId=7ef25e5346b, topicName=敏感性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJnkE6UvGFfMS41qV0RicWvVTTeLMicqibeZH5GqO4YhNicyl1Y9jFhylIUBn9ntPYy9jhk5hrfic5cRYw/132, createdBy=5f822500020, createdName=ms5236388012055669, createdTime=Fri Oct 27 02:07:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498309, encodeId=db7d1498309c4, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Fri Oct 27 02:07:00 CST 2017, time=2017-10-27, status=1, ipAttribution=)]
    2017-10-27 zhaohui6731
  2. [GetPortalCommentsPageByObjectIdResponse(id=1267570, encodeId=d2a8126e570af, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Oct 27 02:07:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297822, encodeId=2172129e82276, content=<a href='/topic/show?id=4eca5598c7' target=_blank style='color:#2F92EE;'>#C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5598, encryptionId=4eca5598c7, topicName=C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20b5274, createdName=JR19860219, createdTime=Fri Oct 27 02:07:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388380, encodeId=4a0213883809d, content=<a href='/topic/show?id=7ef25e5346b' target=_blank style='color:#2F92EE;'>#敏感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57534, encryptionId=7ef25e5346b, topicName=敏感性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJnkE6UvGFfMS41qV0RicWvVTTeLMicqibeZH5GqO4YhNicyl1Y9jFhylIUBn9ntPYy9jhk5hrfic5cRYw/132, createdBy=5f822500020, createdName=ms5236388012055669, createdTime=Fri Oct 27 02:07:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498309, encodeId=db7d1498309c4, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Fri Oct 27 02:07:00 CST 2017, time=2017-10-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1267570, encodeId=d2a8126e570af, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Oct 27 02:07:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297822, encodeId=2172129e82276, content=<a href='/topic/show?id=4eca5598c7' target=_blank style='color:#2F92EE;'>#C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5598, encryptionId=4eca5598c7, topicName=C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20b5274, createdName=JR19860219, createdTime=Fri Oct 27 02:07:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388380, encodeId=4a0213883809d, content=<a href='/topic/show?id=7ef25e5346b' target=_blank style='color:#2F92EE;'>#敏感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57534, encryptionId=7ef25e5346b, topicName=敏感性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJnkE6UvGFfMS41qV0RicWvVTTeLMicqibeZH5GqO4YhNicyl1Y9jFhylIUBn9ntPYy9jhk5hrfic5cRYw/132, createdBy=5f822500020, createdName=ms5236388012055669, createdTime=Fri Oct 27 02:07:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498309, encodeId=db7d1498309c4, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Fri Oct 27 02:07:00 CST 2017, time=2017-10-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1267570, encodeId=d2a8126e570af, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Oct 27 02:07:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297822, encodeId=2172129e82276, content=<a href='/topic/show?id=4eca5598c7' target=_blank style='color:#2F92EE;'>#C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5598, encryptionId=4eca5598c7, topicName=C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20b5274, createdName=JR19860219, createdTime=Fri Oct 27 02:07:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388380, encodeId=4a0213883809d, content=<a href='/topic/show?id=7ef25e5346b' target=_blank style='color:#2F92EE;'>#敏感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57534, encryptionId=7ef25e5346b, topicName=敏感性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJnkE6UvGFfMS41qV0RicWvVTTeLMicqibeZH5GqO4YhNicyl1Y9jFhylIUBn9ntPYy9jhk5hrfic5cRYw/132, createdBy=5f822500020, createdName=ms5236388012055669, createdTime=Fri Oct 27 02:07:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498309, encodeId=db7d1498309c4, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Fri Oct 27 02:07:00 CST 2017, time=2017-10-27, status=1, ipAttribution=)]

相关资讯

心力衰竭病人恶化和低水平的维生素C和高水平hs-CRP相关

2011年美国心脏协会会议报道,低水平的维生素C与高水平的高敏C-反应蛋白(hs-CRP)和短期无主要心脏问题或心力衰竭病人的死亡有关。     与食物中摄入高含量维生素C的人群相比,研究中低维生素C摄入的心力衰竭病人,可能具有2.4倍高水平的hsCRP,是炎症和心脏疾病危险因素的指标。这项研究首次证明,低维生素C摄入量与心力衰竭病人的糟糕结果有关。  

Am J Cardiol:肥胖为高敏C反应蛋白升高重要预测因素

  美国学者的一项研究表明,肥胖为高敏C反应蛋白(hs-CRP)升高的最重要预测因素。论文于2012年11月5日在线发表于《美国心脏病学杂志》(Am J Cardiol)。   此项研究从前瞻性人群中纳入289例患者。对多种潜在预测因素与hs-CRP的相关性进行评估。对潜在混淆因素进行校正之后,利用双变量和多变量线性回归模型对肥胖、体育活动、抑郁及其他数种潜在因素进行分析。

Diabetes Care:hs-CRP可预测糖尿病肾病发生风险(DDCRT7注册研究)

一项来自日本研究观察到血清超敏C反应蛋白(hs-CRP)与糖尿病肾病发生发展风险之间的关系。这项研究由Yasuaki Hayashino教授及其团队进行,属于日本糖尿病登记中心的注册研究--Diabetes Distress and Care Registry at Tenri Study(DDCRT7)。研究结果2014年08月28日的Diabetes Care杂志上,这是一项前瞻性队列研究。本

hs-CRP示曲妥珠单抗心脏毒性

  美国和澳大利亚学者4月4日在线发表于《乳腺癌研究和治疗》(Breast Cancer Research and Treatment)杂志的一项研究表明,定期监测高敏C反应蛋白(hs–CRP)有望用于预测曲妥珠单抗诱发的早期乳腺癌患者的无症状心脏毒性。   该研究前瞻性地纳入了54例人表皮生长因子受体2(HER2)阳性早期乳腺癌患者,并评估了患者血清脑利